A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory have developed a ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948. The company’s DELigase platform allows for targeted protein modulation ...

Dyno’s Psi-Phi generative protein design and agentic interfaces provide versatile AI models and agents that connect physical outcomes with computational workflows Dyno Therapeutics, Inc., a genetic ...

Traditional biologics manufacturing, reliant on sequential batch processing operations, faces significant limitations such as low productivity, lengthy processing times, and frequent manual ...

Machine-learning platform enables signal peptide-informed discovery of small molecules that selectively inhibit protein secretion allowing for the degradation of disease-related proteins at the point ...

SEOUL, South Korea--(BUSINESS WIRE)--Galux, a South Korea-based biotech pioneering AI-driven protein therapeutics design, today announced the successful completion of a $29 million (KRW 42 billion) ...

Some drug treatments, particularly those that include high-dose protein-based therapeutics, are only available as an intravenous (IV) infusion. These protein therapeutics, which need to be delivered ...

A research team led by Purdue University's W. Andy Tao has discovered a new type of protein modification related to cellular ...

Chemists from ETH Zurich have found a way to produce poorly soluble proteins by caging a uniquely reactive boron compound. This method opens up new possibilities for the synthesis of tailored protein ...

This webinar explores how refining transfection workflows and culture conditions can significantly improve efficiency and cell viability, enabling more consistent protein production.

Rock Springs Capital Management bought 46,497 shares of Kymera Therapeutics in the fourth quarter, with an estimated trade value of $3.14 million (based on quarterly average pricing). Meanwhile, the ...